Results 1 to 10 of about 82,220 (258)
Infectious retinitis associated with JAK inhibitors: the ongoing duality of JAK inhibitors. [PDF]
Int J Retina VitreousPurpose To discuss the recent evidence that Janus kinase (JAK) inhibitors can cause viral retinitis. Methods A commentary on the case report in this issue and a review of cases in the literature.
Pulido JS, Mano F, Casella M, Ishida S.
europepmc +5 more sources
JAK Inhibitors in Psoriatic Disease
Clinical, Cosmetic and Investigational Dermatology, 2023 Matteo Megna,1 Luca Potestio,1 Angelo Ruggiero,1 Sara Cacciapuoti,1 Francesco Maione,2 Marco Tasso,3 Francesco Caso,3,* Luisa Costa3,* 1Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples,
Luisa Costa +2 more
exaly +6 more sources
Immunological Medicine, 2023 Among various tyrosine kinases, a family of Janus kinases (JAK) has been elucidated as key players in signal transduction from vital cytokine receptors, such as interleukins and interferons.
Hideto Kameda
doaj +3 more sources
JAK inhibitors in rheumatology
Immunological Medicine, 2023 Janus kinase inhibitors (JAKis) are a group of drugs with a different mechanism of action from biologics and are most rapidly uptaken in the rheumatology field.
Kunihiro Yamaoka, Kenji Oku
doaj +3 more sources
New insights into IFN-γ in rheumatoid arthritis: role in the era of JAK inhibitors
Immunological Medicine, 2020 The treatment of rheumatoid arthritis (RA) is now entering a new era, the era of Janus kinase (JAK) inhibitors. JAK inhibitors target multiple cytokines including IL-6 and exhibit a beneficial treatment effect in patients with RA and inadequate response ...
Masaru Kato
exaly +2 more sources
Frontiers in Pharmacology, 2022 Background: Due to the lack of comprehensive evidence based on prospective studies, the efficacy and safety of Janus Kinase (JAK) inhibitors (including tofacitinib, ruxolitinib, baricitinib, ritlecitinib and brepocitinib) for alopecia areata (AA) are yet
Xiaoyan Nie
exaly +3 more sources
Janus kinase inhibitors in autoimmune bullous diseases
Frontiers in Immunology, 2023 Autoimmune bullous disease (AIBD) is a severe skin disorder caused by autoantibodies that target intercellular or cell-matrix adhesion proteins.
Dawei Huang +9 more
doaj +1 more source
JAK Inhibitors in Rheumatoid Arthritis
European Medical Journal Allergy & Immunology, 2022 JAK inhibitors (JAKi) are targeted, small-molecule, disease-modifying therapies that are the newest class of treatments to emerge for the management of rheumatoid arthritis (RA) and the first oral disease-modifying anti-rheumatic drugs (DMARD) to ...
Kathryn Biddle +2 more
doaj +1 more source
JID Innovations, 2023 Recently, Jak inhibitors such as baricitinib, upadacitinib, and abrocitinib were approved for the treatment of atopic dermatitis (AD) in addition to biologics, including dupilumab, tralokinumab, and nemolizumab. The increase in treatment options can be a
Masahiro Kamata, Yayoi Tada
doaj +1 more source
ACR Open Rheumatology, 2022 Objective Janus kinase (JAK) inhibition effectively treats immune‐mediated inflammatory diseases (IMIDs); however, concern over the risk of major adverse cardiac events (MACE) and venous thromboembolism (VTE) remains. We aimed to evaluate the safety (VTE
Muhammad Haisum Maqsood +5 more
doaj +1 more source